Literature DB >> 22301150

Two distinct broadly neutralizing antibody specificities of different clonal lineages in a single HIV-1-infected donor: implications for vaccine design.

Mattia Bonsignori1, David C Montefiori, Xueling Wu, Xi Chen, Kwan-Ki Hwang, Chun-Yen Tsao, Daniel M Kozink, Robert J Parks, Georgia D Tomaras, John A Crump, Saidi H Kapiga, Noel E Sam, Peter D Kwong, Thomas B Kepler, Hua-Xin Liao, John R Mascola, Barton F Haynes.   

Abstract

Plasma from a small subset of subjects chronically infected with HIV-1 shows remarkable magnitude and breadth of neutralizing activity. From one of these individuals (CH0219), we isolated two broadly neutralizing antibodies (bnAbs), CH01 and VRC-CH31, from two clonal lineages of memory B cells with distinct specificities (variable loop 1 and 2 [V1V2] conformational specificity and CD4-binding site specificity, respectively) that recapitulate 95% of CH0219 serum neutralization breadth. These data provide proof of concept for an HIV-1 vaccine that aims to elicit bnAbs of multiple specificities.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22301150      PMCID： PMC3318651          DOI： 10.1128/JVI.07163-11

Source DB:  PubMed          Journal:  J Virol        ISSN： 0022-538X            Impact factor:   5.103


  25 in total

1.  Polyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individuals.

Authors:  Georgia D Tomaras; James M Binley; Elin S Gray; Emma T Crooks; Keiko Osawa; Penny L Moore; Nancy Tumba; Tommy Tong; Xiaoying Shen; Nicole L Yates; Julie Decker; Constantinos Kurt Wibmer; Feng Gao; S Munir Alam; Philippa Easterbrook; Salim Abdool Karim; Gift Kamanga; John A Crump; Myron Cohen; George M Shaw; John R Mascola; Barton F Haynes; David C Montefiori; Lynn Morris
Journal:  J Virol       Date:  2011-08-17       Impact factor: 5.103

2.  Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41.

Authors:  M B Zwick; A F Labrijn; M Wang; C Spenlehauer; E O Saphire; J M Binley; J P Moore; G Stiegler; H Katinger; D R Burton; P W Parren
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

3.  Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C.

Authors:  James M Binley; Elizabeth A Lybarger; Emma T Crooks; Michael S Seaman; Elin Gray; Katie L Davis; Julie M Decker; Diane Wycuff; Linda Harris; Natalie Hawkins; Blake Wood; Cory Nathe; Douglas Richman; Georgia D Tomaras; Frederic Bibollet-Ruche; James E Robinson; Lynn Morris; George M Shaw; David C Montefiori; John R Mascola
Journal:  J Virol       Date:  2008-09-24       Impact factor: 5.103

4.  Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals.

Authors:  Johannes F Scheid; Hugo Mouquet; Niklas Feldhahn; Michael S Seaman; Klara Velinzon; John Pietzsch; Rene G Ott; Robert M Anthony; Henry Zebroski; Arlene Hurley; Adhuna Phogat; Bimal Chakrabarti; Yuxing Li; Mark Connors; Florencia Pereyra; Bruce D Walker; Hedda Wardemann; David Ho; Richard T Wyatt; John R Mascola; Jeffrey V Ravetch; Michel C Nussenzweig
Journal:  Nature       Date:  2009-03-15       Impact factor: 49.962

5.  Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody.

Authors:  D R Burton; J Pyati; R Koduri; S J Sharp; G B Thornton; P W Parren; L S Sawyer; R M Hendry; N Dunlop; P L Nara
Journal:  Science       Date:  1994-11-11       Impact factor: 47.728

6.  Evaluating neutralizing antibodies against HIV, SIV, and SHIV in luciferase reporter gene assays.

Authors:  David C Montefiori
Journal:  Curr Protoc Immunol       Date:  2005-01

7.  Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1.

Authors:  A Trkola; M Purtscher; T Muster; C Ballaun; A Buchacher; N Sullivan; K Srinivasan; J Sodroski; J P Moore; H Katinger
Journal:  J Virol       Date:  1996-02       Impact factor: 5.103

8.  Analysis of neutralization specificities in polyclonal sera derived from human immunodeficiency virus type 1-infected individuals.

Authors:  Yuxing Li; Krisha Svehla; Mark K Louder; Diane Wycuff; Sanjay Phogat; Min Tang; Stephen A Migueles; Xueling Wu; Adhuna Phogat; George M Shaw; Mark Connors; James Hoxie; John R Mascola; Richard Wyatt
Journal:  J Virol       Date:  2008-11-12       Impact factor: 5.103

9.  Antibody specificities associated with neutralization breadth in plasma from human immunodeficiency virus type 1 subtype C-infected blood donors.

Authors:  Elin S Gray; Natasha Taylor; Diane Wycuff; Penny L Moore; Georgia D Tomaras; Constantinos Kurt Wibmer; Adrian Puren; Allan DeCamp; Peter B Gilbert; Blake Wood; David C Montefiori; James M Binley; George M Shaw; Barton F Haynes; John R Mascola; Lynn Morris
Journal:  J Virol       Date:  2009-06-24       Impact factor: 5.103

Review 10.  Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine?

Authors:  Leonidas Stamatatos; Lynn Morris; Dennis R Burton; John R Mascola
Journal:  Nat Med       Date:  2009-08       Impact factor: 53.440
View more
  111 in total

1.  Global panel of HIV-1 Env reference strains for standardized assessments of vaccine-elicited neutralizing antibodies.

Authors:  Allan deCamp; Peter Hraber; Robert T Bailer; Michael S Seaman; Christina Ochsenbauer; John Kappes; Raphael Gottardo; Paul Edlefsen; Steve Self; Haili Tang; Kelli Greene; Hongmei Gao; Xiaoju Daniell; Marcella Sarzotti-Kelsoe; Miroslaw K Gorny; Susan Zolla-Pazner; Celia C LaBranche; John R Mascola; Bette T Korber; David C Montefiori
Journal:  J Virol       Date:  2013-12-18       Impact factor: 5.103

2.  Heavy chain-only IgG2b llama antibody effects near-pan HIV-1 neutralization by recognizing a CD4-induced epitope that includes elements of coreceptor- and CD4-binding sites.

Authors:  Priyamvada Acharya; Timothy S Luongo; Ivelin S Georgiev; Julie Matz; Stephen D Schmidt; Mark K Louder; Pascal Kessler; Yongping Yang; Krisha McKee; Sijy O'Dell; Lei Chen; Daniel Baty; Patrick Chames; Loïc Martin; John R Mascola; Peter D Kwong
Journal:  J Virol       Date:  2013-07-10       Impact factor: 5.103

Review 3.  Broadly neutralizing antibodies and the search for an HIV-1 vaccine: the end of the beginning.

Authors:  Peter D Kwong; John R Mascola; Gary J Nabel
Journal:  Nat Rev Immunol       Date:  2013-09       Impact factor: 53.106

4.  Broadly Neutralizing Human Immunodeficiency Virus Type 1 Antibody Gene Transfer Protects Nonhuman Primates from Mucosal Simian-Human Immunodeficiency Virus Infection.

Authors:  Kevin O Saunders; Lingshu Wang; M Gordon Joyce; Zhi-Yong Yang; Alejandro B Balazs; Cheng Cheng; Sung-Youl Ko; Wing-Pui Kong; Rebecca S Rudicell; Ivelin S Georgiev; Lijie Duan; Kathryn E Foulds; Mitzi Donaldson; Ling Xu; Stephen D Schmidt; John-Paul Todd; David Baltimore; Mario Roederer; Ashley T Haase; Peter D Kwong; Srinivas S Rao; John R Mascola; Gary J Nabel
Journal:  J Virol       Date:  2015-08       Impact factor: 5.103

5.  NFPws: a web server for delineating broadly neutralizing antibody specificities from serum HIV-1 neutralization data.

Authors:  Nagarajan Raju; Ian Setliff; Ivelin S Georgiev
Journal:  Bioinformatics       Date:  2019-09-15       Impact factor: 6.937

Review 6.  Strategies to guide the antibody affinity maturation process.

Authors:  Nicole A Doria-Rose; M Gordon Joyce
Journal:  Curr Opin Virol       Date:  2015-04-24       Impact factor: 7.090

7.  HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1.

Authors:  Till Schoofs; Florian Klein; Malte Braunschweig; Edward F Kreider; Anna Feldmann; Lilian Nogueira; Thiago Oliveira; Julio C C Lorenzi; Erica H Parrish; Gerald H Learn; Anthony P West; Pamela J Bjorkman; Sarah J Schlesinger; Michael S Seaman; Julie Czartoski; M Juliana McElrath; Nico Pfeifer; Beatrice H Hahn; Marina Caskey; Michel C Nussenzweig
Journal:  Science       Date:  2016-05-05       Impact factor: 47.728

Review 8.  Immunising with the transmembrane envelope proteins of different retroviruses including HIV-1: a comparative study.

Authors:  Joachim Denner
Journal:  Hum Vaccin Immunother       Date:  2012-12-18       Impact factor: 3.452

9.  Comparison of viral Env proteins from acute and chronic infections with subtype C human immunodeficiency virus type 1 identifies differences in glycosylation and CCR5 utilization and suggests a new strategy for immunogen design.

Authors:  Li-Hua Ping; Sarah B Joseph; Jeffrey A Anderson; Melissa-Rose Abrahams; Jesus F Salazar-Gonzalez; Laura P Kincer; Florette K Treurnicht; Leslie Arney; Suany Ojeda; Ming Zhang; Jessica Keys; E Lake Potter; Haitao Chu; Penny Moore; Maria G Salazar; Shilpa Iyer; Cassandra Jabara; Jennifer Kirchherr; Clement Mapanje; Nobubelo Ngandu; Cathal Seoighe; Irving Hoffman; Feng Gao; Yuyang Tang; Celia Labranche; Benhur Lee; Andrew Saville; Marion Vermeulen; Susan Fiscus; Lynn Morris; Salim Abdool Karim; Barton F Haynes; George M Shaw; Bette T Korber; Beatrice H Hahn; Myron S Cohen; David Montefiori; Carolyn Williamson; Ronald Swanstrom
Journal:  J Virol       Date:  2013-04-24       Impact factor: 5.103

10.  Neutralizing antibodies to HIV-1 envelope protect more effectively in vivo than those to the CD4 receptor.

Authors:  Amarendra Pegu; Zhi-yong Yang; Jeffrey C Boyington; Lan Wu; Sung-Youl Ko; Stephen D Schmidt; Krisha McKee; Wing-Pui Kong; Wei Shi; Xuejun Chen; John-Paul Todd; Norman L Letvin; Jinghe Huang; Martha C Nason; James A Hoxie; Peter D Kwong; Mark Connors; Srinivas S Rao; John R Mascola; Gary J Nabel
Journal:  Sci Transl Med       Date:  2014-07-02       Impact factor: 17.956
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.